Satoru Suzuki

Satoru Suzuki

Auto-generated profile, based on publicly available information

Satoru Suzuki

Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2000 in Clinical Immunology
Verified
Journal Article
Closed access
SFShigeharu Fujieda
Shigeharu Fujieda
SSSatoru Suzukib
Satoru Suzukib
HSHiroshi Sunagaa
Hiroshi Sunagaa
HYHideyuki Yamamotoa
Hideyuki Yamamotoa
MSMizue Sekia
Mizue Sekia
HSHitoshi Saito
Hitoshi Saito

1 July 2019 in Medicine
Verified
Journal Article
Open access
KFKoichiro Fujisue
Koichiro Fujisue
TTTakanori Tokitsu
Takanori Tokitsu
EYEiichiro Yamamoto
Eiichiro Yamamoto
DSDaisuke Sueta
Daisuke Sueta
MTMasafumi Takae
Masafumi Takae
KTKenichi Tsujita
Kenichi Tsujita
The prognostic significance of systemic atherothrombosis in heart failure (HF) with preserved ejection fraction (HFpEF) remains unclear. This study aimed to investigate the relation between the presence of polyvascular disease (PVD) and cardiovascular outcomes in HFpEF patients. A total of 510 consecutive HFpEF patients were prospectively observed for up to 1500 days or until occurrence of cardiovascular events. PVD was defined as ≥2 coexistence of coronary artery disease, peripheral arterial disease, and cerebrovascular disease. Overall, 124 cardiovascular events were observed during follow-up (median: 1430 days). Kaplan–Meier curve showed HFpEF with PVD (n = 84) experienced more cardiovascular events than did those without PVD patients (44.0% vs 20.4%, log-rank: P < .001). Multivariable Cox proportional hazards analysis with significant factors from univariate analysis showed the presence of PVD (hazard ratio [HR]: 2.875, 95% [CI]: 1.894–4.365, P < .001), previous HF hospitalization (HR: 1.578, 95% CI: 1.031–2.414, P = .036), hemoglobin (HR: 0.889, 95% CI: 0.805–0.983, P = .021), serum sodium (HR: 0.946, 95% CI 0.896–1.000, P = .048), ln-BNP (per 1.0, HR: 1.255, 95% CI: 1.055–1.494, P = .010), and E/e’ (HR: 1.047, 95% CI: 1.020–1.075, P < .001) significantly predicted future cardiovascular events. Multivariable Cox hazard analysis with 4 established factors (age, BNP, diabetes mellitus, and previous HF hospitalization) from the I-PRESERVE (Irbesartan in HFpEF) study showed PVD was independently associated with cardiovascular events in HFpEF patients (HR: 2.562, 95% CI: 1.715–3.827, P < .001). The presence of PVD is significantly associated with cardiovascular events in HFpEF, suggesting the importance of screening PVD in HFpEF.

1 January 2014 in Endocrine Journal
Verified
Journal Article
Open access
PDF file
YKYuki Kobayashi
Yuki Kobayashi
MTMasahiro Takei
Masahiro Takei
YOYohsuke Ohkubo
Yohsuke Ohkubo
Yukinari KakizawaYukinari Kakizawa
Yukinari Kakizawa
HMHisanori Matoba
Hisanori Matoba
MKMitsuhisa Komatsu
Mitsuhisa Komatsu
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies

1 April 2020 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
SSSatoru Suzuki
Satoru Suzuki
Yoshiyuki ShirasakaYoshiyuki Shirasaka
Yoshiyuki Shirasaka
RORen Okada
Ren Okada
AEAkari Eguchi
Akari Eguchi
KHKISHIMOTO HISANAO
KISHIMOTO HISANAO
KIKatsuhisa Inoue
Katsuhisa Inoue